Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Change in Receivables (2024 - 2025)

ImmunityBio (IBRX) has disclosed Change in Receivables for 4 consecutive years, with $10.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Receivables rose 681.54% to $10.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $40.2 million, a 1603.86% increase, with the full-year FY2025 number at $40.2 million, up 1603.86% from a year prior.
  • Change in Receivables was $10.6 million for Q4 2025 at ImmunityBio, up from $9.9 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $14.7 million in Q1 2025 to a low of -$1.8 million in Q4 2024.